HSD-016

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H21F7N2O3S
Molecular Weight	514.457
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H]1CN(CCN1S(=O)(=O)C2=CC(=CC=C2)[C@@](C)(O)C(F)(F)F)C3=CC=C(F)C=C3C(F)(F)F

InChI

InChIKey=ZWASRJHIEFYJGL-BFUOFWGJSA-N

InChI=1S/C21H21F7N2O3S/c1-13-12-29(18-7-6-15(22)11-17(18)20(23,24)25)8-9-30(13)34(32,33)16-5-3-4-14(10-16)19(2,31)21(26,27)28/h3-7,10-11,13,31H,8-9,12H2,1-2H3/t13-,19-/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21736359 | https://clinicaltrials.gov/ct2/show/NCT00739232

HSD-016 was discovered as an orally efficacious 11β-hydroxysteroid dehydrogenase type 1 inhibitor for the treatment of diabetes. The phase I in clinical trials for the drug was completed; however, information about further studies is not available.

Originator

Approval Year

PubMed

Title	Date	PubMed
Synthesis of potent and orally efficacious 11β-hydroxysteroid dehydrogenase type 1 inhibitor HSD-016.	2011-09-02	21736359

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Oral

Name

Type

Language

HSD-016

Common Name

English

BENZENEMETHANOL, 3-(((2R)-4-(4-FLUORO-2-(TRIFLUOROMETHYL)PHENYL)-2-METHYL-1-PIPERAZINYL)SULFONYL)-.ALPHA.-METHYL-.ALPHA.-(TRIFLUOROMETHYL)-, (.ALPHA.R)-

Preferred Name

English

Code System Code Type Description

EPA CompTox

DTXSID20241559